Torque Teno Virus Load Is Associated With Subclinical Alloreactivity in Kidney Transplant Recipients: A Prospective Observational Trial.


Journal

Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144

Informations de publication

Date de publication:
01 09 2021
Historique:
pubmed: 16 2 2021
medline: 3 11 2021
entrez: 15 2 2021
Statut: ppublish

Résumé

Nonpathogenic torque teno viruses (TTVs) are highly prevalent in transplant recipients and associated with immunosuppression. Studies in kidney transplant patients have proposed assessment of TTV load for risk stratification of clinically overt graft rejection. The value of TTV quantification in the context of subclinical rejection has not been evaluated. In this prospective trial, 307 consecutive kidney transplant recipients were subjected to per-protocol monitoring of plasma TTV. TTV was analyzed in the context of protocol biopsies (n = 82), scheduled 1 year posttransplantation. TTV load at the time of biopsy was lower in recipients with rejection (n = 19; according to Banff, including borderline changes suspicious for acute T cell-mediated rejection) than those without rejection (n = 63) whereby each log increase in TTV copies/mL decreased the risk for rejection by 9% (risk ratio 0.91, 95% confidence interval, 0.85-0.97; P = 0.004). Development of chronic lesions (cg, cv, ci, ct, ah, ptcml) was associated with the number of days with a TTV load <1 × 106 copies/mL between months 3 and 12 posttransplant (β 0.07, 95% confidence interval, 0.01-0.14; P = 0.02). This trial demonstrates an association between TTV and subclinical graft rejection in kidney transplant recipients. A TTV load <1 × 106 copies/mL suggests suboptimal immunosuppression.

Sections du résumé

BACKGROUND
Nonpathogenic torque teno viruses (TTVs) are highly prevalent in transplant recipients and associated with immunosuppression. Studies in kidney transplant patients have proposed assessment of TTV load for risk stratification of clinically overt graft rejection. The value of TTV quantification in the context of subclinical rejection has not been evaluated.
METHODS
In this prospective trial, 307 consecutive kidney transplant recipients were subjected to per-protocol monitoring of plasma TTV. TTV was analyzed in the context of protocol biopsies (n = 82), scheduled 1 year posttransplantation.
RESULTS
TTV load at the time of biopsy was lower in recipients with rejection (n = 19; according to Banff, including borderline changes suspicious for acute T cell-mediated rejection) than those without rejection (n = 63) whereby each log increase in TTV copies/mL decreased the risk for rejection by 9% (risk ratio 0.91, 95% confidence interval, 0.85-0.97; P = 0.004). Development of chronic lesions (cg, cv, ci, ct, ah, ptcml) was associated with the number of days with a TTV load <1 × 106 copies/mL between months 3 and 12 posttransplant (β 0.07, 95% confidence interval, 0.01-0.14; P = 0.02).
CONCLUSIONS
This trial demonstrates an association between TTV and subclinical graft rejection in kidney transplant recipients. A TTV load <1 × 106 copies/mL suggests suboptimal immunosuppression.

Identifiants

pubmed: 33587432
doi: 10.1097/TP.0000000000003619
pii: 00007890-202109000-00032
pmc: PMC8376270
doi:

Substances chimiques

Immunosuppressive Agents 0

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2112-2118

Informations de copyright

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.

Déclaration de conflit d'intérêts

The authors declare no conflicts of interest.

Références

Chand S, Atkinson D, Collins C, et al. The spectrum of renal allograft failure. PLoS One. 2016;11:e0162278.
Anglicheau D, Naesens M, Essig M, et al. Establishing biomarkers in transplant medicine: a critical review of current approaches. Transplantation. 2016;100:2024–2038.
Andrews LM, Li Y, De Winter BCM, et al. Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients. Expert Opin Drug Metab Toxicol. 2017;13:1225–1236.
Focosi D, Antonelli G, Pistello M, et al. Torquetenovirus: the human virome from bench to bedside. Clin Microbiol Infect. 2016;22:589–593.
Strassl R, Doberer K, Rasoul-Rockenschaub S, et al. Torque teno virus for risk stratification of acute biopsy-proven alloreactivity in kidney transplant recipients. J Infect Dis. 2019;219:1934–1939.
Solis M, Velay A, Gantner P, et al. Torquetenovirus viremia for early prediction of graft rejection after kidney transplantation. J Infect. 2019;79:56–60.
Schiemann M, Puchhammer-Stöckl E, Eskandary F, et al. Torque teno virus load-inverse association with antibody-mediated rejection after kidney transplantation. Transplantation. 2017;101:360–367.
Doberer K, Schiemann M, Strassl R, et al. Torque teno virus for risk stratification of graft rejection and infection in kidney transplant recipients-A prospective observational trial. Am J Transplant. 2020;20:2081–2090.
Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–470.
Loupy A, Haas M, Roufosse C, et al. The Banff 2019 kidney meeting report (I): updates on and clarification of criteria for T cell- and antibody-mediated rejection. Am J Transplant. 2020;20:2318–2331.
Maggi F, Pifferi M, Fornai C, et al. TT virus in the nasal secretions of children with acute respiratory diseases: relations to viremia and disease severity. J Virol. 2003;77:2418–2425.
Nankivell BJ, Agrawal N, Sharma A, et al. The clinical and pathological significance of borderline T cell-mediated rejection. Am J Transplant. 2019;19:1452–1463.
Wiebe C, Rush DN, Gibson IW, et al. Evidence for the alloimmune basis and prognostic significance of Borderline T cell-mediated rejection. Am J Transplant. 2020;20:2499–2508.
Mehta RB, Tandukar S, Jorgensen D, et al. Early subclinical tubulitis and interstitial inflammation in kidney transplantation have adverse clinical implications. Kidney Int. 2020;98:436–447.
Mcculloch E, Montgomery D, Maggi F, et al. External Quality Assessment (EQA) Pilot Study for Molecular Diagnostics of Torque Teno Virus (TTV). In: 22nd Annual Meeting of the European Society for Clinical Virology; Copenhagen, DK: European Society for Clinical Virology; 2019.
Kulifaj D, Durgueil-Lariviere B, Meynier F, et al. Development of a standardized real time PCR for torque teno viruses (TTV) viral load detection and quantification: a new tool for immune monitoring. J Clin Virol. 2018;105:118–127.

Auteurs

Konstantin Doberer (K)

Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.

Frederik Haupenthal (F)

Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.

Maja Nackenhorst (M)

Department of Pathology, Medical University of Vienna, Vienna, Austria.

Florian Bauernfeind (F)

Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.

Florentina Dermuth (F)

Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.

Michael Eigenschink (M)

Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.

Martin Schiemann (M)

Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.

Johannes Kläger (J)

Department of Pathology, Medical University of Vienna, Vienna, Austria.

Irene Görzer (I)

Center for Virology, Medical University of Vienna, Vienna, Austria.

Farsad Eskandary (F)

Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.

Roman Reindl-Schwaighofer (R)

Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.

Željko Kikić (Ž)

Department of Urology, Medical University of Vienna, Vienna, Austria.

Georg Böhmig (G)

Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.

Robert Strassl (R)

Division of Clinical Virology, Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.

Heinz Regele (H)

Department of Pathology, Medical University of Vienna, Vienna, Austria.

Elisabeth Puchhammer-Stöckl (E)

Center for Virology, Medical University of Vienna, Vienna, Austria.

Gregor Bond (G)

Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH